Acceptance of adjuvant therapy and quality of life issues
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The acceptance of adjuvant treatment for early breast cancer (EBC) is dependent on the information that women are given about: available options, likely therapeutic gains, side effect profiles, convenience of treatment as well as their prior knowledge, experience and expectations. Acceptability in terms of adherence to treatment is then dependent on the actual burden experienced and the impact this has on quality of life (QoL). Studies show that >40% women do not adhere to tamoxifen because of side effects affecting QoL. The burden of adjuvant therapy may be underestimated by clinicians; thus, when options are discussed, treatments may appear more favourable and acceptable than they really are. The aim of the newer aromatase inhibitors (AIs) is to enhance efficacy without the associated unacceptable side effects. Interim results from the QoL sub-protocols of three trials, ATAC, IES and MA-17, provide useful indications of acceptability and the impact that AIs have on QoL. Data from patient self-report questionnaires and preference studies are needed to inform treatment recommendations and to aid the development of ameliorative interventions needed to accompany the most efficacious therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
Fromme, E. K., Eilers, K. M., Mori, M., Hsieh, Y.-C., & Beer, T. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.025 · Cited by 555
Cited by
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi326 · Cited by 1,127
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
Ziller, V., Kalder, M., Albert, U.-S., Holzhauer, W., Ziller, M., Wagner, U., & Hadji, P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn646 · Cited by 263
Curigliano, G., Viale, G., Bagnardi, V., Fumagalli, L., Locatelli, M., Rotmensz, N., Ghisini, R., Colleoni, M., Munzone, E., Veronesi, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0962 · Cited by 259
Melisko, M. E., Goldman, M. E., Hwang, J., De Luca, A., Fang, S., Esserman, L. J., Chien, A. J., Park, J. W., & Rugo, H. S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3904 · Cited by 155
Cahir, C., Guinan, E., Dombrowski, S. U., Sharp, L., & Bennett, K. (2015) · Patient Education and Counseling · doi:10.1016/j.pec.2015.05.013 · Cited by 84
Metadata
- Authors
- Fallowfield, L.
- Venue
- The Breast
- Publisher
- Elsevier BV
- Published
- 2005-12
- Volume
- 14
- Issue
- 6
- Pages
- 612-616
- ISSN
- 0960-9776 (ISSN-L)
- OpenAlex
- W2029680563
- Cited by
- 52
- References
- 2
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.